| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD6482 | GDSC1000 | pan-cancer | AAC | 0.15 | 3e-06 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.19 | 1e-05 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.2 | 7e-05 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | -0.18 | 0.0002 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0002 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0003 |
| mRNA | PD318088 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0004 |
| mRNA | selumetinib:PLX-4032 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0004 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | -0.17 | 0.0005 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.16 | 0.0006 |